| Date Filed | Type | Description |
| 12/02/2016 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)] |
| 12/02/2016 |
8-K
| Quarterly results |
| 12/01/2016 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 12/01/2016 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 12/01/2016 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 12/01/2016 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 12/01/2016 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 12/01/2016 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 11/30/2016 |
SC 13E3/A
| Form SC 13E3/A - Going private transaction by certain issuers: [Amend] |
| 11/15/2016 |
8-K
| Form 8-K - Current report |
| 11/14/2016 |
10-Q
| Quarterly Report for the period ended September 30, 2016 |
| 08/16/2016 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/16/2016 |
8-K
| Quarterly results |
| 08/15/2016 |
10-Q
| Quarterly Report for the period ended June 30, 2016 |
| 08/11/2016 |
SC 13E3/A
| Form SC 13E3/A - Going private transaction by certain issuers [Amend] |
| 08/11/2016 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition |
| 08/04/2016 |
SC 13E3/A
| Form SC 13E3/A - Going private transaction by certain issuers [Amend] |
| 08/04/2016 |
PRER14A
| Form PRER14A - Preliminary Proxy Soliciting materials |
| 07/25/2016 |
SC 13E3/A
| Form SC 13E3/A - Going private transaction by certain issuers [Amend] |
| 07/25/2016 |
PRER14A
| Form PRER14A - Preliminary Proxy Soliciting materials |
| 06/24/2016 |
PREM14A
| Form PREM14A - Preliminary proxy statements relating to merger or acquisition |
| 06/20/2016 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership [Amend] |
| 06/20/2016 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
| 06/20/2016 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 06/15/2016 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits|
Docs:
|
"Response Biomedical Corp. Announces Voting Results VANCOUVER, B.C., June 13, 2016 - Response Biomedical Corp. , in accordance with the requirements of the Toronto Stock Exchange, is pleased to announce the results of voting at its 2016 Annual General and Special Meeting of Shareholders held earlier today. A total of 6,110,535 common shares were represented at the meeting, representing approximately 62% of the issued and outstanding common shares of the Company. Shareholders voted as follows: 1. Election of Directors By resolution passed by show of hands, the number of Directors of the Company was set at seven. By resolution passed by ballot vote, the following seven nominees proposed by Management were elected as Directors of the Company to hold office until the next Annual Meeting of Shar..." |
|
| 05/20/2016 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans |
| 05/19/2016 |
8-K
| Quarterly results|
Docs:
|
"Response Biomedical Corp. Announces First Quarter 2016 Financial Results VANCOUVER, British Columbia – May 16, 2016 - Response Biomedical Corp. a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today reported financial results for its first quarter ended March 31, 2016, including a 2016 GAAP net loss of $, or $ per share, compared with a GAAP net loss of $, or $ per share in 2015, and 2016 negative Adjusted EBITDA of $, compared with a negative Adjusted EBITDA of $ in 2015. “Sales in China in the first quarter of 2016 continued to be a challenge for us. We were successful in increasing non-China sales by 16%, improving gross margin by 10 percentage points and reducing operating costs by 15% thereby reducing our Adjusted EBITDA l..." |
|
| 05/16/2016 |
10-Q
| Quarterly Report for the period ended March 31, 2016 |
| 05/12/2016 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements |
| 04/29/2016 |
10-K/A
| Annual Report for the period ended December 31, 2015 [amend] |
| 03/24/2016 |
10-K
| Annual Report for the period ended December 31, 2015 |
| 03/23/2016 |
8-K
| Quarterly results|
Docs:
|
"Response Biomedical Corp. Announces Fourth Quarter and Fiscal 2015 Financial Results VANCOUVER, British Columbia – March 21, 2016 - Response Biomedical Corp. a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today reported financial results for its fourth quarter and year ended December 31, 2015, including a 2015 GAAP net loss of $, or $ per share, compared with a GAAP net loss of $, or $ per share in 2014, and 2015 Adjusted EBITDA of $822,000, compared with a negative Adjusted EBITDA of $ in 2014. “We are pleased to report our first full year of Adjusted EBITDA profitable growth with a 40% increase to $15.4 million in total revenue in 2015 - $3.4 million in Joinstar collaboration revenue and $12.0 million in product sales. This..." |
|
| 11/12/2015 |
10-Q
| Quarterly Report for the period ended September 30, 2015 |
| 08/14/2015 |
10-Q
| Quarterly Report for the period ended June 30, 2015 |
|